Bioengineers at The University of Texas at Dallas have created a novel gene-delivery system that shuttles a gene into a cell, but only for a temporary stay, providing a potential new gene-therapy strategy for treating disease.
The approach offers distinct advantages over other types of gene therapies under investigation, said Richard Taplin Moore MS’11, a doctoral student in bioengineering in the Erik Jonsson School of Engineering and Computer Science. He is lead author of a study describing the new technique in the Jan. 30 issue of the journal Nucleic Acids Research.
“In other gene therapy approaches, the therapeutic genetic messages being delivered can persist for a long time in the patient, potentially lasting for the patient’s entire lifetime,” Moore said. “This irreversibility is one reason gene therapies are so difficult to get approved.”
The UT Dallas study describes proof-of-concept experiments in which a gene carrying instructions for making a particular protein is ordered to self-destruct once the cell has “read” the instructions and made a certain quantity of the protein. In its experiments with isolated human kidney cells, the research team successfully delivered — and then destroyed — a test gene that makes a red fluorescent protein.
More research is needed to determine whether and how well the system might work in living organisms. But Moore said the ultimate goal is to refine the method to deliver genes that produce therapeutic proteins or drugs. The nature of the gene delivery system offers more control over how much protein the gene produces in cells or tissues. Because it does not alter the cell permanently, the method also sidesteps potential health problems that can occur if a gene is delivered to the wrong place in a cell’s genome.
“Our goal was to create a delivery system for therapeutic genes that would self-destruct, giving us more control over the delivered DNA by limiting the time it resides in cells,” Moore said.
Read more: Team Creates New Approach to Gene Therapy
The Latest on: Gene Therapy
[google_news title=”” keyword=”Gene Therapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Gene Therapy
- Gene Therapy Market 2017 to 2021 – Overview and scope, market Size, industry Trends, Outlook, Opportunityon October 16, 2019 at 11:57 pm
Oct 17, 2019 (AmericaNewsHour) -- According to a new report published by Polaris Market Research, the global gene therapy market is anticipated to reach USD 4,300 million by 2021. The demand for gene ...
- BioIVT Acquires PPA Research Group, Increasing its Ability to Support Drug Development, Cell and Gene Therapy Researchon October 16, 2019 at 7:41 pm
Leukopaks are used during drug development for target discovery, validation, lead optimization, and toxicity assays as well as for stem cell and gene therapy research. In addition to having its own ...
- Gene therapy’s slump & Gilead’s new CFOon October 16, 2019 at 6:10 pm
Alexion acquiring Achillion to expand reach into rare, immune-related… Alexion acquiring Achillion to expand reach into rare, immune-related disease An updated guide to the changing science of flu… An ...
- Gene-Therapy Treatment May Help People with Macular Degenerationon October 16, 2019 at 3:33 pm
Researchers at multiple sites are currently conducting a phase I clinical trial on a gene therapy that could help patients get fewer injections in their eye to treat the condition. AMD develops when ...
- ‘Gene therapy headwinds’ are blamed for biotech stock woeson October 15, 2019 at 4:58 am
Blame a slump in gene therapy stocks in the second half of the year for the relative underperformance of the biotech sector, according to a new analysis. A proprietary index of 64 drug makers ...
- Transduction optimization of AAV vectors for human gene therapy of glaucoma and their reversed cell entry characteristicson October 14, 2019 at 11:28 am
Tyrosine scAAV2 capsid mutants increased transduction in HTM cultured cells and all TM-outflow layers of perfused postmortem human eyes. These studies provide the first serotype optimization for gene ...
- The Biotech Sector Is Lagging. Blame Gene Therapy Stocks, Analysts Say.on October 14, 2019 at 7:29 am
To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.
- Gene Therapy Market Focus to Boost Revenue with Massive Growthon October 14, 2019 at 4:25 am
Oct 14, 2019 (Hitech News Daily via COMTEX) -- The gene therapy market is estimated to reach $4,402 million by 2023, registering a CAGR of 33.3% from 2017 to 2023. North America is the highest ...
- Early Promise for Gene Therapy in AMDon October 13, 2019 at 2:32 pm
SAN FRANCISCO -- Patients with severe neovascular age-related macular degeneration (AMD) had long-term vision stabilization and anatomic improvement following a single treatment with an ...
- In-office gene therapy injection maintains BCVA through 24 weeks in wet AMD patientson October 13, 2019 at 11:04 am
SAN FRANCISCO — Patients with wet age-related macular degeneration in the OPTIC trial treated with one in-office injection of ADVM-022, a gene therapy specifically designed for long-term intraocular ...
via Bing News